全文获取类型
收费全文 | 31728篇 |
免费 | 3006篇 |
国内免费 | 53篇 |
专业分类
耳鼻咽喉 | 368篇 |
儿科学 | 1084篇 |
妇产科学 | 681篇 |
基础医学 | 4547篇 |
口腔科学 | 536篇 |
临床医学 | 3324篇 |
内科学 | 6062篇 |
皮肤病学 | 427篇 |
神经病学 | 3130篇 |
特种医学 | 1097篇 |
外国民族医学 | 3篇 |
外科学 | 4032篇 |
综合类 | 785篇 |
一般理论 | 43篇 |
预防医学 | 3196篇 |
眼科学 | 945篇 |
药学 | 2399篇 |
中国医学 | 26篇 |
肿瘤学 | 2102篇 |
出版年
2021年 | 411篇 |
2020年 | 330篇 |
2019年 | 485篇 |
2018年 | 510篇 |
2017年 | 420篇 |
2016年 | 451篇 |
2015年 | 540篇 |
2014年 | 771篇 |
2013年 | 1133篇 |
2012年 | 1618篇 |
2011年 | 1701篇 |
2010年 | 870篇 |
2009年 | 868篇 |
2008年 | 1489篇 |
2007年 | 1661篇 |
2006年 | 1596篇 |
2005年 | 1603篇 |
2004年 | 1584篇 |
2003年 | 1390篇 |
2002年 | 1425篇 |
2001年 | 841篇 |
2000年 | 862篇 |
1999年 | 820篇 |
1998年 | 436篇 |
1997年 | 330篇 |
1996年 | 374篇 |
1995年 | 310篇 |
1994年 | 283篇 |
1993年 | 282篇 |
1992年 | 601篇 |
1991年 | 609篇 |
1990年 | 582篇 |
1989年 | 575篇 |
1988年 | 506篇 |
1987年 | 509篇 |
1986年 | 518篇 |
1985年 | 454篇 |
1984年 | 390篇 |
1983年 | 355篇 |
1982年 | 270篇 |
1981年 | 220篇 |
1980年 | 202篇 |
1979年 | 373篇 |
1978年 | 265篇 |
1977年 | 199篇 |
1976年 | 203篇 |
1975年 | 180篇 |
1974年 | 207篇 |
1973年 | 218篇 |
1972年 | 189篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Morgan GJ Davies FE Gregory WM Szubert AJ Bell SE Drayson MT Owen RG Ashcroft AJ Jackson GH Child JA;National Cancer Research Institute Haematological Oncology Clinical Studies Group 《Blood》2012,119(23):5374-5383
The Medical Research Council Myeloma IX Trial (ISRCTNG8454111) examined traditional and thalidomide-based induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly diagnosed multiple myeloma. Overall survival (OS) and skeletal-related event (SRE) data have been reported for the overall trial population. The present analysis investigated optimal therapy regimens for different patient populations in Myeloma IX. Patients were assigned to intensive or nonintensive treatment pathways and randomized to induction cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) versus cyclophosphamide, thalidomide, and dexamethasone (CTD; intensive) or melphalan and prednisolone versus attenuated oral CTD (CTDa; nonintensive). Patients were also randomized to ZOL or CLO. In the nonintensive pathway, CTDa produced better responses and lower SRE rates than melphalan and prednisolone. ZOL improved OS compared with CLO independently of sex, stage, or myeloma subtype, most profoundly in patients with baseline bone disease or other SREs. In patients treated for ≥ 2 years, ZOL improved OS compared with CLO from randomization (median not reached for either; P = .02) and also from first on-study disease progression (median, 34 months for ZOL vs 27 months for CLO; P = .03). Thalidomide-containing regimens had better efficacy than traditional regimens, and ZOL demonstrated greater benefits than CLO. 相似文献
993.
Schmid C Labopin M Nagler A Niederwieser D Castagna L Tabrizi R Stadler M Kuball J Cornelissen J Vorlicek J Socié G Falda M Vindeløv L Ljungman P Jackson G Kröger N Rank A Polge E Rocha V Mohty M;Acute Leukaemia Working Party of the European Group for Blood Marrow Transplantation 《Blood》2012,119(6):1599-1606
Because information on management and outcome of AML relapse after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning (RIC) is scarce, a retrospective registry study was performed by the Acute Leukemia Working Party of EBMT. Among 2815 RIC transplants performed for AML in complete remission (CR) between 1999 and 2008, cumulative incidence of relapse was 32% ± 1%. Relapsed patients (263) were included into a detailed analysis of risk factors for overall survival (OS) and building of a prognostic score. CR was reinduced in 32%; remission duration after transplantation was the only prognostic factor for response (P = .003). Estimated 2-year OS from relapse was 14%, thereby resembling results of AML relapse after standard conditioning. Among variables available at the time of relapse, remission after HSCT > 5 months (hazard ratio [HR] = 0.50, 95% confidence interval [CI], 0.37-0.67, P < .001), bone marrow blasts less than 27% (HR = 0.53, 95% CI, 0.40-0.72, P < .001), and absence of acute GVHD after HSCT (HR = 0.67, 95% CI, 0.49-0.93, P = .017) were associated with better OS. Based on these factors, 3 prognostic groups could be discriminated, showing OS of 32% ± 7%, 19% ± 4%, and 4% ± 2% at 2 years (P < .0001). Long-term survival was achieved almost exclusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidation. 相似文献
994.
Paterson A Mockridge CI Adams JE Krysov S Potter KN Duncombe AS Cook SJ Stevenson FK Packham G 《Blood》2012,119(7):1726-1736
B-cell receptor and microenvironment-derived signals promote accumulation of chronic lymphocytic leukemia (CLL) cells through increased proliferation and/or decreased apoptosis. In this study, we investigated the regulation of BIM, a proapoptotic BCL2-related protein, which is tightly regulated by phosphorylation. Surface IgM stimulation increased phosphorylation of 2 BIM isoforms, BIM(EL) and BIM(L), in a subset of CLL samples. In contrast, in normal B cells, anti-IgM triggered selective phosphorylation of BIM(EL) only. In CLL, anti-IgM-induced BIM phosphorylation correlated with unmutated IGHV gene status and with progressive disease. Strikingly, it was also associated with progressive disease within the mutated IGHV gene subset. BIM phosphorylation was dependent on MEK1/2 kinase activity, and we identified BIM(EL) serine 69, previously linked to pro-survival responses, as the major site of phosphorylation in CLL and in Ramos cells. BIM(EL)/BIM(L) phosphorylation was associated with release of the pro-survival protein MCL1. Coculture of CLL cells with HK cells, a model of the CLL microenvironment, promoted CLL cell survival and was associated with MEK1/2 activation and BIM(EL) phosphorylation. Hence, BIM phosphorylation appears to play a key role in apoptosis regulation in CLL cells, potentially coordinating antigen and microenvironment-derived survival signals. Antigen-mediated effects on BIM may be an important determinant of clinical behavior. 相似文献
995.
Heart disease and stroke statistics--2012 update: a report from the American Heart Association 总被引:1,自引:0,他引:1
Roger VL Go AS Lloyd-Jones DM Benjamin EJ Berry JD Borden WB Bravata DM Dai S Ford ES Fox CS Fullerton HJ Gillespie C Hailpern SM Heit JA Howard VJ Kissela BM Kittner SJ Lackland DT Lichtman JH Lisabeth LD Makuc DM Marcus GM Marelli A Matchar DB Moy CS Mozaffarian D Mussolino ME Nichol G Paynter NP Soliman EZ Sorlie PD Sotoodehnia N Turan TN Virani SS Wong ND Woo D Turner MB;American Heart Association Statistics Committee Stroke Statistics Subcommittee 《Circulation》2012,125(1):e2-e220
996.
Samarasinghe S Steward C Hiwarkar P Saif MA Hough R Webb D Norton A Lawson S Qureshi A Connor P Carey P Skinner R Vora A Pelidis M Gibson B Stewart G Keogh S Goulden N Bonney D Stubbs M Amrolia P Rao K Meyer S Wynn R Veys P 《British journal of haematology》2012,157(3):339-346
We retrospectively analysed the outcome of consecutive children with idiopathic severe aplastic anaemia in the United Kingdom who received immunosuppressive therapy (IST) or matched unrelated donor (MUD) haematopoietic stem cell transplantation (HSCT). The 6-month cumulative response rate following rabbit antithymocyte globulin (ATG)/ciclosporin (IST) was 32·5% (95% CI 19·3-46·6) (n = 43). The 5-year estimated failure-free survival (FFS) following IST was 13·3% (95% confidence interval [CI] 4·0-27·8). In contrast, in 44 successive children who received a 10-antigen (HLA-A, -B, -C, -DRB1, -DQB1) MUD HSCT there was an excellent estimated 5-year FFS of 95·01% (95% CI 81·38-98·74). Forty of these children had failed IST previously. HSCT conditioning was a fludarabine, cyclophosphamide and alemtuzumab (FCC) regimen and did not include radiotherapy. There were no cases of graft failure. Median donor chimerism was 100% (range 88-100%). A conditioning regimen, such as FCC that avoids total body irradiation is ideally suited in children. Our data suggest that MUD HSCT following IST failure offers an excellent outcome and furthermore, if a suitable MUD can be found quickly, MUD HSCT may be a reasonable alternative to IST. 相似文献
997.
Dignan FL Amrolia P Clark A Cornish J Jackson G Mahendra P Scarisbrick JJ Taylor PC Shaw BE Potter MN;Haemato-oncology Task Force of British Committee for Standards in Haematology;British Society for Blood Marrow Transplantation 《British journal of haematology》2012,158(1):46-61
A joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Society for Bone Marrow Transplantation (BSBMT) has reviewed the available literature and made recommendations for the diagnosis and management of chronic graft-versus-host disease (GvHD). This guideline includes recommendations for the diagnosis and staging of chronic GvHD as well as primary treatment and options for patients with steroid-refractory disease. The goal of treatment should be the effective control of GvHD while minimizing the risk of toxicity and relapse. 相似文献
998.
Diagnosis and management of acute graft-versus-host disease 总被引:1,自引:0,他引:1
Dignan FL Clark A Amrolia P Cornish J Jackson G Mahendra P Scarisbrick JJ Taylor PC Hadzic N Shaw BE Potter MN;Haemato-oncology Task Force of British Committee for Standards in Haematology;British Society for Blood Marrow Transplantation 《British journal of haematology》2012,158(1):30-45
A joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Society for Bone Marrow Transplantation (BSBMT) has reviewed the available literature and made recommendations for the diagnosis and management of acute graft-versus-host disease. This guideline includes recommendations for the diagnosis and grading of acute graft-versus-host disease as well as primary treatment and options for patients with steroid-refractory disease. The goal of treatment should be effective control of graft-versus-host disease while minimizing risk of toxicity and relapse. 相似文献
999.
1000.
Sofat N Robertson SD Hermansson M Jones J Mitchell P Wait R 《Rheumatology international》2012,32(9):2809-2817
Cartilage destruction is a hallmark of osteoarthritis (OA) and is characterized by increased protease activity resulting in the degradation of critical extracellular matrix (ECM) proteins essential for maintaining cartilage integrity. Tenascin-C (TN-C) is an ECM glycoprotein, and its expression is upregulated in OA cartilage. We aimed to investigate the presence of TN-C fragments in arthritic cartilage and establish whether they promote cartilage degradation. Expression of TN-C and its fragments was evaluated in cartilage from subjects undergoing joint replacement surgery for OA and RA compared with normal subjects by western blotting. The localization of TN-C in arthritic cartilage was also established by immunohistochemistry. Recombinant TN-C fragments were then tested to evaluate which regions of TN-C are responsible for cartilage-degrading activity in an ex vivo cartilage explant assay measuring glycosaminoglycan (GAG) release, aggrecanase and matrix metalloproteinase (MMP) activity. We found that specific TN-C fragments are highly upregulated in arthritic cartilage. Recombinant TN-C fragments containing the same regions as those identified from OA cartilage mediate cartilage degradation by the induction of aggrecanase activity. TN-C fragments mapping to the EGF-L and FN type III domains 3-8 of TN-C had the highest levels of aggrecan-degrading ability that was not observed either with full-length TN-C or with other domains of TN-C. TN-C fragments represent a novel mechanism for cartilage degradation in arthritis and may present new therapeutic targets for the inhibition of cartilage degradation. 相似文献